Comparing Therapeutic Effect of Enoxaparin and Intravenous Heparin therapy in Percutaneous Coronary Intervention (PCI)
Abdolrasool Moloudi*, Alireza Ray and Babak HeidariEmam Ali Heart Hospital, Shahid Beheshti Blvd., Kermanshah, Iran.
Abstract: Acute stent thrombosis is one of the most important complications of percutaneous coronary intervention (PCI). It is recommended to use anticoagulant drugs to prevent this disease. At present heparin is the most commonly used drug in this field. However, it is used less than intravenous enoxaparin (low molecular weight heparin). In this clinical trial, these two drugs are used during PCI in patients and early nosocomial complications of each of them are considered and evaluated. This study was conducted during 1387-1388 on 304 patients divided into two groups of E (Enoxaparin) and H (Heparin) consisting of 150 patients each. Patients were hospitalized in CCU (Intensive Care Unit) for 48 hours and were evaluated after PCI in terms of acute nosocomial complications. The results of this study are analyzed using T-Test and Logestic Regression. In this study was conducted on 304 patients with an average age of 55±9. Major bleeding, acute vascular occlusion and death were observed in none of these two groups. Minor bleeding and local hematoma in group H are more significantly different from those in group E (p>0.05). 64% and 51% drug-eluting stent was used in groups E and H, respectively. Statistical analysis showed no significant difference between these two groups in terms of drug-eluting stents (p>0.05). In group E, sheath was removed up to one hour after the PCI procedure, while it lasted 7 hours in group H (P=0.000). The present study showed that there is no significant difference between the acute nosocomial complications in PCI patients and the kind of anticoagulant medicine. However, the duration of arterial sheath removal in group E was significantly lower than that in group H.
Keywords: Percutaneous Coronary Angioplasty (PCI); Heparin; Enoxaparin; Early Complications Back to TOC